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Abstract
The nonpathogenic, mutualistic bacteria of the mammalian gastrointestinal tract provide a number 
of benefits to the host. Recent reports have shown how the aggregate genomes of gastrointestinal 
bacteria provide novel benefits by functioning as the third major genome in mammals along with 
the nuclear and mitochondrial genomes. Consequently, efforts are underway to elucidate the 
complexity of the organisms comprising the unique ecosystem of the gastrointestinal tract, as well 
as those associated with other epidermal surfaces. The current knowledge of the gastrointestinal 
microbiome, its relationship to human health and disease with a particular focus on mammalian 
physiology, and efforts to alter its composition as a novel therapeutic approach are reviewed.
In recent years there has been renewed interest in the enteric microorganisms that inhabit the 
mammalian gastrointestinal (GI) tract, commonly referred to as the GI microbiota. In 
particular, focus has been on the variation that occurs in the microbiota composition and on 
specific bacterial species that can antagonize or ease intestinal or other diseases. However, 
the idea that GI microorganisms are associated with a person's well-being is not new. 
Almost a century ago Ilya Ilyich Mechnikov (also known as Elie Metchnikoff), the 1908 
Nobel Laureate in Physiology or Medicine for his work on phagocytosis, postulated in 
Prolongation of Life: Optimistic Studies that certain bacteria could improve the intestinal 
health of the host (Metchnikoff 1908). With the advent of genome-scale technologies and 
the ability to perform metagenomics, the dynamic interplay between a host and its GI 
microbiota and how these interactions contribute to disease are beginning to be elucidated 
(Turnbaugh et al. 2007).
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The GI microbiota is a complex community of bacteria, archaea, and eukarya. The bacterial 
fraction is believed to contain more than 500 different species and can reach numbers of 
1012–1014 cells/ml of luminal contents (Ley et al. 2006; Whitman et al. 1998), with the 
highest densities residing in the colon. In addition to the numbers of bacteria in the GI tract 
being much greater, the diversity of phyla in the GI tract is also greater than in any other 
host environment like the skin, oral cavity, or reproductive tract (Dethlefsen et al. 2007; 
Grice et al. 2009; Nasidze et al. 2009; Zhou et al. 2009). In fact, the number of bacterial 
cells in the GI tract is greater than the total number of somatic cells in the mammalian body 
by an order of magnitude. With the exceptionally high numbers and such a diverse 
community of microorganisms, it is not surprising that the cumulative genomes of the GI 
microbiome are estimated to contain over 100 times as many genes as the mammalian 
nuclear genome (Gill et al. 2006). The microbiome harbors genes that code the components 
of many metabolic processes not found in mammalian cells but that are nonetheless essential 
for optimal health, such as the ability to degrade indigestible dietary components like fiber 
and plant cell wall polysaccharides (Brulc et al. 2009; Flint et al. 2007; Pryde et al. 2002). 
Consequently, the relationships between mammalian hosts and their GI microbiota are more 
mutualistic than commensal. The GI microorganisms have access to an unlimited supply of 
nutrition and in return the host is provided with readily absorbable nutrients (Rowland et al. 
1985). Furthermore, the GI microbiota stimulate normal immune maturation (Bauer et al. 
2006; Mazmanian et al. 2005), provide defense against pathogens through pathogen 
interference (Bernet-Camard et al. 1997), impart GI mucosal barrier stability (Gotteland et 
al. 2001), and alter the impact of toxicants and xenobiotics (Meinl et al. 2009; Swann et al. 
2009). Since the well-being and phenotypic state of a host depends on the intimate 
association with its GI microbiota, it has been suggested that mammals can be considered as 
superorganisms, composed of an amalgam of both prokaryotic and eukaryotic cells 
(Goodacre 2007; Lederberg 2000).
Coevolution of the GI microbiota with its host
More than 55 bacterial divisions exist on Earth, yet only two of these deep evolutionary 
phyla, Bacteroidetes and Firmicutes, are predominant in the GI microbiota, suggesting that 
the mammalian GI tract is a relatively exclusive environment (Backhed et al. 2005). 
However, there is an abundance of species from the two primary phyla represented in the 
mammalian microbiota. Supporting the idea of the GI tract as a unique environment is the 
fact that GI microorganisms are rarely found living independently outside their host. 
Conversely, studies on germ-free (GF) mice, which lack all microorganisms, demonstrate 
the host's dependence on the GI microbiota for normal physiological development and 
homeostasis. For example, GF mice exhibit elongated villi, an oversized cecum, and altered 
susceptibility to obesity (Backhed et al. 2007; Thompson and Trexler 1971), conditions that 
are reversed when GF mice are associated with a specific pathogen-free (SPF) microbiota. 
The inability of organisms to survive independently (GI microbiota) or to maintain normal 
health (mammalian hosts) is a strong indication of coevolved mutualism.
Coevolution is defined as the mutual evolutionary influence between species and has been 
extensively documented for humans and infectious microorganisms (Brunham et al. 1993). 
For example, the adaptation of Helicobacter pylori with its human host has been used to 
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independently trace the migration of early humans from northern Africa (Linz et al. 2007). 
The coevolution of hosts with their GI microbiota has resulted in a cooperative relationship 
that has shaped the biology and genomes of these mutualistic partners (Ley et al. 2006).
In order to reside in the unique, relatively exclusive GI niche, microorganisms must contain 
a battery of genes that are dedicated to their persistence, such as genes coding for bile-salt 
hydrolases and mucus/fibronectin binding proteins. These are evident in the genome 
sequence of Bacteroides thetaiotaomicron, a prominent member of the GI microbiota, where 
the representation of predicted glycosylhydrolases far exceeds that of any other sequenced 
bacterial genome (Xu et al. 2003). In addition, B. thetaiotaomicron has the ability to utilize 
host-derived glycans. Thus, a symbiotic relationship exists where a prominent member of 
the GI microbiota can break down dietary components for host use, while the host provides 
an ecosystem with a rich energy source in the form of glycans and other dietary components. 
Additional evidence for coevolution of GI microbiota and their hosts is displayed in the 
genomes of Lactobacillus acidophilus (Altermann et al. 2005) and L. johnsonii (Pridmore et 
al. 2004). The genomes of these two Lactobacillus species harbor a number of genes coding 
for proteins that process indigestible dietary components that can be utilized by the host but 
lack genes responsible for the synthesis of amino acids and purine nucleotides, indicating a 
strong dependence on the host.
Similar to the influence of the host on the microbiota, the microorganisms inhabiting the GI 
tract likely affected mammalian evolution. It has been demonstrated that the human GI 
microbiome is significantly enriched with genes for the metabolism of glycans, amino acids, 
and xenobiotics when compared to the human genome (Gill et al. 2006; Meinl et al. 2009; 
Swann et al. 2009). Thus, the GI microbiome has genes that the mammalian host did not 
need to evolve independently and allows the host to obtain nutrients from food sources that 
would otherwise be indigestible (Brulc et al. 2009; Flint et al. 2007; Pryde et al. 2002). 
Supporting the strong link between the GI microbiome and its host is the fact that the 
composition of the GI microbiota changes with age, mirroring changes in diet that occur 
between milk-fed infants and adults and into the elderly years (Mariat et al. 2009; Sela et al. 
2008). It is therefore likely that the GI microbiome aided the acceleration of early 
mammalian evolution by supporting consumption and use of novel food constituents (Ley et 
al. 2008).
The gastrointestinal microbiome
Most species of bacteria that inhabit the mammalian GI tract are currently unculturable and 
amenable only to molecular analysis (Eckburg et al. 2005; Hayashi et al. 2005; Table 1). 
Until recently, the majority of nucleic acid sequences obtained from analysis of the 
mammalian GI microbiome were from the 16S rDNA genes, which have been widely used 
for the qualitative and quantitative analyses of the microbiota constituents (Alexander et al. 
2006; Heilig et al. 2002; Sarma-Rupavtarm et al. 2004). Analysis of the mammalian GI 
microbiome has now entered the metagenomic era (characterization of complex bacterial 
populations). Metagenomic analysis on the human distal colonic microbiome identified 
distinctive functional attributes encoded by the member microorganisms (Gill et al. 2006). 
Thousands of GI microbiome sequences were analyzed from random DNA libraries 
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generated from fecal specimens collected from one male and one female subject with no 
known health problems or antibiotic exposure. The GI microbiome of both subjects 
displayed an enrichment of genes specific to metabolic processes such as energy production 
and conversion, transport, and metabolism of carbohydrates, amino acids, and coenzymes as 
well as secondary metabolite biosynthesis, transport, and catabolism. In addition, a 
metagenomic study of the microbiomes from adults and children at various ages 
demonstrated that preweaned infants have simpler but more variable microbiota than 
weaned children or adults, who are more complex but also more uniform (Kurokawa et al. 
2007). An important example is Bifidobacterium longum subsp. infantis, which has adapted 
to utilize milk-borne molecules that have little nutritive value to the neonatal host (Sela et al. 
2008). New high-throughput sequencing technologies have even supported interrogation of 
ancient human microbiomes from preserved paleofecal deposits (Tito et al. 2008).
Complementary investigations have focused on the metabolic properties of specific 
Bacteroides spp. since they account for a large proportion of the constituents of the GI 
microbiota. The genome sequence of B. thetaiotaomicron, which represents 12% of GI 
Bacteroides and 6% of the entire GI microbiota based on 16S rDNA analysis, proves its 
unique niche in the host GI tract (Xu et al. 2003); B. thetaiotaomicron contains an unusually 
large number of genes responsible for the metabolism of carbohydrates. In addition, the 
genome sequences of B. vulgatus and B. distasonis, which represent 31 and 0.8% of total GI 
Bacteroides, respectively, prove that many genes in the microbiome are dedicated to the 
acquisition, breakdown, or synthesis of carbohydrates (Xu et al. 2007).
The importance of the metabolic activities encoded by the GI microbiome is reflected in the 
fact that the composition of the GI microbiota is strongly influenced by the host's diet. For 
example, a reduction in dietary carbohydrates leads to reduced levels of Roseburia spp., 
Eubacterium rectale, and Bifidobacterium spp., but there is no change in Bacteroides spp. 
(Duncan et al. 2007). The levels of some constituents of the GI microbiota can be altered 
indirectly by diet because of their dependence on the metabolic production of other 
constituents that are directly affected by diet (Belenguer et al. 2006).
Although diet has a pronounced influence on the GI microbiota, a growing body of evidence 
suggests that host genetics can also influence the composition of the GI microbiota 
(Zoetendal et al. 2001). Comparisons of microbiota from mono- and dizygotic twins indicate 
that host genetic factors may influence the composition of the microbiota (Stewart et al. 
2005; Van de Merwe et al. 1983). Host-influenced changes in the composition of the 
microbiota may be a mechanism by which host genetics contributes to obesity if the selected 
microbiota have increased capacity for energy harvest from the diet (Turnbaugh et al. 2006). 
Importantly, individuals with shared phenotypic characteristics, e.g., obesity, can have 
different microbiota while sharing a “core microbiome” at the gene level (Turnbaugh et al. 
2009). The role of host genetics in modulating GI microbiota composition has been 
confirmed using mice in controlled environments. Inbred strains of mice differ in the 
quantity of various members of the GI microbiota and these differences are maintained even 
when mice from different strains cohabitate (Alexander et al. 2006). Similar experiments 
indicate that gender, age, and presence of pathogenic bacteria in the GI tract influence 
colonization dynamics (Ge et al. 2006).
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The GI microbiota and disease
Although the GI microbiota is essential for the health of the host, it is also associated with a 
number of intestinal disorders and susceptibility to systemic diseases. The mutualistic 
relationship of the mammalian host with its GI microbiota is based on tolerance. Reduced or 
altered host tolerance to GI microorganisms can lead to inflammatory disorders such as 
inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Moreover, studies 
have also correlated the composition of the microbiota with systemic diseases like cancer 
and obesity.
IBD
Crohn's disease (CD) and ulcerative colitis (UC), collectively known as IBD, are disorders 
of unknown cause and are characterized by recurrent intestinal inflammation. IBD is 
believed to result from one or a combination of factors including genetic-based host 
susceptibility, the GI microbiota, and a dysfunctional immune response (Sartor 1997). The 
GI microbiota, which are thought to be a major source of antigens contributing to abnormal 
immune responses, differ among individuals at different stages of CD and UC (Bibiloni et 
al. 2006). Differences in the GI microbiota may precede the onset of inflammation (Nones et 
al. 2009). More recent analyses have found that a subset of individuals with CD and UC 
have a depletion of commensal bacteria from the phyla Bacteroidetes and Firmicutes, 
suggesting that IBD may represent a spectrum of disease states (Frank et al. 2007). The most 
convincing evidence for the association of GI microbiota with IBD comes from gnotobiotic 
(defined microbiota) studies in mouse models of colitis (Kuhn et al. 1993), which 
demonstrated that mucosal inflammation results when interleukin-10 (Il10)-deficient mice 
are colonized by normal members of the GI microbiota. Confirming this association, 
inflammation is absent from these mutant mice when they are maintained GF.
IBS
IBS is a chronic GI disorder characterized by abdominal pain, cramping, diarrhea, and/or 
constipation (Quigley 2006; Ringel et al. 2001). Traditionally, IBS has been considered a 
disorder that is associated with GI hypersensitivity, which leads to pain, and GI motor 
dysfunction, which leads to diarrhea or constipation. Randomized studies have implicated 
various factors in this GI disorder, including food allergy, serotonin levels, pathogenic 
bacterial infection and inflammation, alterations in the normal GI microbiota, and host 
genetics (Talley 2006). Because IBS is a heterogeneous disorder, it is possible that there are 
heterogeneous etiologies for the different subtypes of the disorder: diarrhea-predominant 
IBS (D-IBS), constipationpredominant IBS (C-IBS), mixed-bowel-habit IBS (MIBS), or 
postinfectious IBS (PI-IBS). Recent investigations have demonstrated that the composition 
of the GI microbiome of individuals with IBS differs from that of healthy controls (Kassinen 
et al. 2007), implicating intestinal bacteria in the pathogenesis of this disorder. Moreover, 
intestinal inflammation has been demonstrated in patients with IBS (Liebregts et al. 2007; 
O'Mahony et al. 2005), further implicating GI microbiota in the pathogenesis of IBS. 
However, to date there is no clear picture of how an altered GI microbiota is associated with 
intestinal inflammation, altered GI hypersensitivity, or motor dysfunction.
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As might be expected, cancers of the colon are most strongly associated with the GI 
microbiota. Germ-free Il10-deficient mice are resistant to IBD and subsequent 
colitisassociated colon cancer (CAC), but if conventionalized, they are highly susceptible to 
CAC development with the azoxymethane carcinogen model (Uronis et al. 2009). Similarly, 
transforming growth factor β1 (Tgfb1) null mice that are colonized by a conventional 
microbiota develop colon cancer, while those that are raised GF do not (Engle et al. 2002). 
The susceptibility to colon cancer of mice with perturbed transforming growth factor β 
(TGFB) signaling, like the Smad3 null, Rag2 null, and Tgfb1 null mouse models (Erdman et 
al. 2009; Maggio-Price et al. 2006), has been attributed to Helicobacter spp. or other 
proinflammatory bacteria in the colon. Unlike the TGFB-driven models, ApcMin mice, raised 
under GF conditions, show only a modest reduction in the number of intestinal polyps (Dove 
et al. 1997), suggesting that the microbiota can have differential influences on molecularly 
distinct colon cancers. In addition to modulating the inflammatory system, the GI microbiota 
also produces butyrate, a potent histone deacetylase inhibitor that can alter epigenetic 
programming of colonocytes and has been implicated in the prevention of colon cancer 
(Balamurugan et al. 2008). Differences in the composition of the GI microbiota may also 
contribute to ethnic differences in colon cancer incidence (O'Keefe et al. 2007). The role of 
the GI microbiota in cancer susceptibility may even extend beyond the colon; it was recently 
reported that members of the GI microbiota can increase susceptibility to mammary 
adenocarcinomas in mice (Rao et al. 2006).
Obesity
The traditional view of obesity is centered on nutrition and host genetics (Rankinen et al. 
2006). However, studies using mouse models of obesity as well as GF and gnotobiotic mice 
have shown a contributing role of the GI microbiota to obesity (Backhed et al. 2007; Ley et 
al. 2005; Turnbaugh et al. 2007). Consistent with the diet-linked changes in the GI 
microbiota described above, the ratio of the two predominant bacterial divisions, 
Bacteroides and Firmicutes, shifts significantly when comparing normal to diet-induced 
obese mice (Ley et al. 2005). Furthermore, in leptin-deficient obese mice, the number of 
Bacteroides is 50% lower with a subsequent rise in the quantities of Firmicutes compared to 
normal littermates. This observation was also found in obese humans where the numbers of 
organisms from the Bacteroidetes division increased in dieting subjects and correlated with 
weight loss (Kurokawa et al. 2007). These observations did not demonstrate whether a 
change in the Bacteroidetes division is the cause of weight gain or whether it was the effect 
of consuming specific dietary components that selectively enhances the members of this 
bacterial division. However, a recent study demonstrated that an “obese microbiome” can 
promote weight gain in ex-GF mice when compared to ex-GF mice associated with a “lean 
microbiome,” demonstrating that the obesity phenotype can be transmissible through the 
microbiome (Turnbaugh et al. 2008).
One mechanism by which the microbiome contributes to obesity appears to be through 
modulation of host metabolism. Ex-GF mice that are conventionalized with a normal GI 
microbiota have a dramatic increase in weight compared to their GF littermates, even though 
they consume less food. The GI microbiota suppress expression of angiopoietin-like 4 
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(Angpt14, formerly called fasting-induced adipose factor or Fiaf), which causes the 
deposition of triglycerides in adipocytes. GF mice lacking Angpt14 lose resistance to diet-
induced obesity (Backhed et al. 2007), which implicates the GI microbiota as a contributor 
to obesity not only by increasing the capacity for harvesting sugars from the diet, but also by 
modulating the host's processing and storage of fats. The GI microbiota can also have direct 
effects on host physiology. For example, the GI microbiota can convert choline into 
methylamines, thus reducing the availability of choline in mice maintained on a high-fat diet 
(Dumas et al. 2006). Consequences of choline metabolism by the microbiota are mimicking 
choline-deficient diets and inducing nonalcoholic fatty liver disease.
Other systemic diseases
The GI microbiota also has pronounced effects on host physiology beyond the intestinal 
tract. Metabolomic differences in the urine of GF and normal microbiota-colonized rats 
(Nicholls et al. 2003) and among humans with different microbiota compositions (Li et al. 
2008) can be readily detected. A more detailed metabolic analysis of various biofluids 
showed that the microbiota impact the homeostasis of a variety of organ systems in mice, 
including altering liver levels of glycine and bile acids and kidney levels of hippurate, 
betaine, and choline (Claus et al. 2008). Similarly, the microbiota cause changes in a variety 
of blood metabolites (Wikoff et al. 2008). The blood metabolomic changes elicited by the 
GI microbiota are similar to those of a drug-like phase II response in the host, suggesting 
that the microbiota may also impact drug metabolizing-capability of the host. The type of 
microbiota also can have differential influences on host physiology (Martin et al. 2007). 
Colonization of GF mice with human neonatal GI microbiota, as opposed to adult GI 
microbiota, causes changes in a highly correlated metabolome network in the plasma and 
urine, indicative of lipid metabolism.
With the range of physiological and metabolic changes to the host attributed to the GI 
microbiota, it is not surprising that systemic diseases can also be influenced by members of 
the GI microbiota. Epidemiological studies have shown that allergic diseases correlate with 
the use of antibiotics and alterations to the GI microbiota (Shreiner et al. 2008). Confirming 
the link between antibiotic use and allergic diseases, mice with antibiotic disruption of the 
GI microbiota have elevated sensitivity to T-cell-mediated airway allergic response that 
requires IL13 (Noverr et al. 2005). More striking are the potential links between the GI 
microbiota and cardiovascular and neurological diseases (Ordovas and Mooser 2006; 
Parracho et al. 2005). For example, the GI microbiota influence myocardial metabolism in 
response to nutrient deprivation (Crawford et al. 2009) and diet-induced improvements in 
hypercholesterolemia (Martinez et al. 2009). In addition, children with autistic spectrum 
disorders have higher levels of Clostridium histolyticum, a known toxin-producer, than 
healthy controls (Parracho et al. 2005).
Microbiota-based therapies
Because the microbiota play an important role in GI and other diseases, numerous studies 
have attempted to exploit beneficial bacteria (probiotics) or compounds that stimulate 
beneficial bacteria (prebiotics) as therapies. Probiotics are live microorganisms that when 
administered in adequate numbers confer a health benefit on the host. It is believed that 
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increasing the numbers of specific organisms within the GI microbiota can have a beneficial 
effect, either directly by regulating the host immune system (O'Mahony et al. 2001; Peran et 
al. 2005; Vinderola et al. 2005) or indirectly by altering the composition or activity of the GI 
microbiota (Tannock et al. 2000).
Most probiotic-mediated therapies to date have focused on IBD. Many different probiotics 
are effective at reducing inflammation in various mouse models of IBD (Prisciandaro et al. 
2009), demonstrating that there is no generalized mode of action for the beneficial effects of 
probiotics. Modulation of the microbiota as a treatment for IBD has been confirmed in 
clinical trials where antibiotics can alleviate inflammatory symptoms and it is a common 
treatment for IBD patients (Bibiloni et al. 2005). Although early probiotic trials in human 
patients with IBD were criticized for their experimental design, a number of double-blind 
placebo-controlled trials for IBS have been performed and clearly demonstrate the beneficial 
effects of probiotics (Gawronska et al. 2007; Guyonnet et al. 2007).
Although recent clinical trials have demonstrated the therapeutic benefit of probiotics for 
treating GI illnesses, the underlying mechanisms contributing to their beneficial effects 
remain relatively unknown. An emerging aspect of probiotic therapy is the heterologous 
expression of novel therapeutic molecules in natural constituents of the GI microbiota. 
Because probiotics in their natural form can reduce symptoms of GI disease in mouse 
models and in human clinical trials (Ouwehand et al. 2002), it is tempting to speculate that 
more effective probiotics can be created through genetic engineering. Initial studies using 
genetically engineered probiotics demonstrated how recombinant lactic acid bacteria can 
enhance lipid digestion (Drouault et al. 2002) and prevent HIV infection (Chang et al. 2003) 
and be used to deliver foreign antigens to mucosal surfaces (Seegers 2002). In addition, it 
has been demonstrated that a recombinant strain of Lactococcus lactis producing mouse 
IL10 is capable of reducing inflammation in the Il10-deficient mouse model (Steidler et al. 
2000). Although this approach failed as a therapeutic in clinical trials, this study 
demonstrated the power of probiotics as delivery vehicles for replacing molecules depleted 
in vivo. Similarly, heterologous expression of trefoil factors in L. lactis acts as a potent 
prophylactic for the treatment of acute colitis in a chemically induced mouse model of 
colitis (Vandenbroucke et al. 2004). More recently, Lactobacillus gasseri, genetically 
engineered to overexpress the antioxidant superoxide dismutase, was shown to decrease 
inflammation and disease in the Il10 mouse model of colitis (Carroll et al. 2007).
Future prospects
Renewed appreciation for the role of GI microorganisms in health and disease has led to the 
Human Gut Microbiome Initiative (Turnbaugh et al. 2007). The objective of this program is 
to sequence and compare the genomes of hundreds of species representing the bacterial 
divisions known to comprise the human distal GI microbiota. Analyzing the combined 
genomes of numerous GI microorganisms will answer important questions about the 
evolution and flexibility of the GI microbiome, including the extent of lateral gene transfer 
between autochthonous (permanent) and allochthonous (transient) GI microorganisms, the 
identification of essential genes required for survival in the GI ecosystem, and the 
mechanisms of interaction between the GI microbiota and the host immune system. Equally 
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important will be the insights gained into the mechanisms by which the GI microbiota 
modulate a diverse array of host phenotypes. Many phenotypes that have been attributed to 
the host in functional genomic studies may in fact result from host-microbiota interactions. 
The GI microbiome is the most malleable of the mammalian “genomes,” whose composition 
has important implications for mammalian functional genomics and links to health and 
disease outcome. An improved knowledge of the composition and function of the GI 
microbiota of humans and model organisms will allow this important third genome of 
mammals to be exploited for new therapeutic approaches to prevent or treat not only GI 
diseases but also systemic diseases like cancer and obesity.
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Table 1
Comparison of human and mouse GI microbiota composition



































Unclassified bacteria 0.09 0.05
Bold = major phyla
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